Table 3.

Correlation (r) of endpoint patient global impression of improvement with changes in variables assessing the emotional well-being domain.

Domain	Duloxetine		Placebo		Combined
Domain	n	r	n	r	n	r
FIQ anxiety	821	0.36	506	0.29	1327	0.35
HAMD anxiety subscale^*	693	0.18	391	0.12	1084	0.17
MFI motivation	498	0.39	295	0.40	93	0.40
HAMD Maier subscale	693	0.32	391	0.23	1084	0.30
FIQ depression	820	0.32	505	0.32	1325	0.34
SF-36 mental health	794	−0.31	489	−0.30	1283	−0.32
BDI loss of pleasure	615	0.29	403	0.23	1018	0.28
BDI pessimism	615	0.20	402	0.24	1017	0.22
EQ5D anxiety/depression	484	0.19	283	0.23	767	0.21
BDI past failure	615	0.18	403	0.09	1018	0.15
BDI sadness	614	0.17	402	0.31	1016	0.24
BDI self-criticalness	615	0.15	403	0.11	1018	0.13
BDI self-dislike	615	0.12	403	0.15	1018	0.14
BDI suicidality	615	0.07	403	0.02	1018	0.06

BDI: Beck Depression Inventory; BPI: Brief Pain Inventory; EQ5D: EuroQol Questionnaire 5 Dimensions; FIQ: Fibromyalgia Impact Questionnaire; HAMD: Hamilton Depression Rating Scale; MFI: Multidimensional Fatigue Inventory; SDS: Sheehan Disability Scale; SF-36: Medical Outcomes Study Short-Form 36.
↵* HAMD items 10–13, 15, 17.